• Icatibant in Viral Infections: Mechanism and Evidence

  2026-09-18

  The 2023 letter by Mustonen and colleagues proposes bradykinin B2-receptor blockade as a host-directed strategy for severe hantavirus disease, linking two PUUV case reports with emerging COVID-19 trial evidence. Its main contribution is mechanistic and hypothesis-generating rather than confirmatory: icatibant may help address capillary leak, but timing, patient selection, and controlled efficacy data remain unresolved.

• Talabostat Mesylate (PT-100): DPP4/FAP Research

  2026-09-18

  Talabostat mesylate, also called PT-100 or Val-boroPro, is an orally active dipeptidyl peptidase inhibitor used to study DPP4/FAP biology. Its strongest value is mechanistic: it enables controlled investigation of protease-dependent immune, stromal, and hematopoietic responses, while available tumor-growth evidence remains model-dependent and limited.

• AICAR: AMPK Activation in Metabolic Research

  2026-09-17

  AICAR is a cell-permeable AMPK activator used to study energy metabolism regulation, inflammatory signaling, and cellular stress protection. Its preclinical value is strongest when pathway engagement, cytokine responses, viability, and model-specific limitations are measured together.

• Ertugliflozin (PF-04971729) Research Workflow

  2026-09-17

  Build reproducible renal transport, diabetes mellitus research, and inflammation-model workflows with the highly selective SGLT2 inhibitor Ertugliflozin (PF-04971729). This guide connects assay setup and formulation control with translational cardiovascular evidence, while emphasizing practical troubleshooting and experimental boundaries.

• Z-WEHD-FMK: Practical Caspase Assay Guidance

  2026-09-16

  This scenario-based guide explains how Z-WEHD-FMK (SKU A1924) can help researchers distinguish inflammatory caspase activity from broader viability effects in cell-based assays. It covers solvent compatibility, protocol design, pyroptosis interpretation, and practical vendor-selection criteria.

• Molidustat (BAY85-3934) Hypoxia Assay Workflow

  2026-09-16

  Molidustat (BAY85-3934) enables controlled hypoxia-inducible factor stabilization for renal anemia, chronic kidney disease, and mechanistic hypoxia studies. This workflow connects HIF-PH inhibition with Septin4–VHL–HIF-1α biology while emphasizing dosing, solvent, and assay controls.

• Berberine Hydrochloride: Research Workflows

  2026-09-15

  Build reproducible metabolic, cancer, and inflammation assays with Berberine hydrochloride while controlling solubility, vehicle exposure, and pathway-specific readouts. This guide connects AMPK and lipid-metabolism workflows with a carefully bounded, hypothesis-generating extension into oxidized self-DNA and inflammasome research.

• TRPV1/TRPA1 Signaling in Nasal TSLP Production

  2026-09-15

  The reference study identifies a calcium-dependent NFAT mechanism linking TRPV1 and TRPA1 activation in nasal epithelial cells to thymic stromal lymphopoietin (TSLP) production. Its combination of pharmacological perturbation, siRNA, calcium chelation, inflammatory-factor profiling, and NFAT localization provides a useful framework for interpreting epithelial ion-channel signaling in upper-airway inflammation.

• AAPH Oxidative Stress Assay Workflows

  2026-09-14

  A scenario-based guide to using AAPH (2,2'-Azobis(2-methylpropionamidine) Dihydrochloride), SKU C5140, in cell, erythrocyte, and lipid-peroxidation assays. It addresses solvent compatibility, protocol design, interpretation limits, and practical reagent selection using product specifications and current ferroptosis literature.

• Targeted CRISPRi of Fabp4 in White Adipocytes

  2026-09-14

  Chung and colleagues developed a nonviral, adipocyte-targeted CRISPR interference system that silences Fabp4 in white adipocytes. In obese mice, this approach reduced body weight and inflammation while improving hepatic steatosis and insulin resistance, providing a tissue-selective framework for metabolic disorder research.

• Neurotensin: GPCR Trafficking Workflow Guide

  2026-09-13

  Neurotensin is a practical Neurotensin receptor 1 activator for connecting receptor signaling with trafficking and miR-133α modulation in gastrointestinal cell models. This guide combines an executable cell-based workflow with interference-aware data practices inspired by a 2024 fluorescence-classification study.

• S100A8/A9 Drives Hypertrophy-to-Heart Failure Transition

  2026-09-11

  A 2025 Theranostics study combines single-cell RNA sequencing with genetic, bone-marrow chimera, coculture, and pharmacological experiments to identify myeloid S100A8/A9 as a regulator of pressure overload-induced heart failure. The work defines a neutrophil-to-macrophage inflammatory axis that links early adaptive hypertrophy to later fibrosis and cardiac dysfunction, while also highlighting practical considerations for studying phosphorylation-dependent signaling.

• Talabostat Mesylate as a FAP Assay Control

  2026-09-11

  Talabostat mesylate (PT-100) can serve as more than a dual DPP4/FAP inhibitor: it is a mechanistic control for testing FAP-dependent activity in tumor models. This guide connects inhibitor perturbation with FAP-sensitive nanoparticle diagnostics, assay design, and interpretation limits.

• 3-Methyladenine in Autophagy Research Workflows

  2026-09-10

  3-Methyladenine provides a practical way to perturb PI3K-dependent autophagy while revealing why flux, timing, and pathway controls matter. This guide translates the estrogen–autophagy findings from a recent multi-organ study into reproducible cell, cancer, and tissue-protection assay strategies.

• CFTRinh-172 Workflows for Epithelial Assays

  2026-09-10

  CFTRinh-172 provides a rapid, selective way to separate CFTR channel activity from trafficking and signaling effects in airway and intestinal models. This guide pairs functional inhibition with surface-abundance assays, practical controls, and troubleshooting for cystic fibrosis research and secretory diarrhea studies.

8068 records 1/538 page Next 12345 下5页 Last page